Organization
Hackensack University Medical Center
18 abstracts
Abstract
First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.Org: KSQ Therapeutics, Cambridge, MA, Roche Pharma Research and Early Development, Roche Innovation Center, Dana-Farber Cancer Institute, Hackensack University Medical Center,
Abstract
Clinical and sociodemographic factors associated with digital health literacy in patients with non-Hodgkin lymphoma or colorectal carcinoma.Org: Hackensack Meridian School of Medicine, Center for Discovery & Innovation, Hackensack Meridian Health, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack University Medical Center,
Abstract
Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody (mAb) MK-0482 + pembrolizumab (pembro) in patients with recurrent inoperable glioblastoma (GBM).Org: Seoul National University Hospital, Asan Medical Center, University of Ulsan College of Medicine, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack University Medical Center,
Abstract
Post-ASCT consolidation with EPD or ERD in patients with high-risk multiple myeloma.Org: Hackensack University Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,
Abstract
Mortality trends (1999-2022) in patients with multiple myeloma with pneumonia, influenza, and COVID-19.Org: Hackensack University Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,
Abstract
Expression of alternatively spliced BCMA RNA with skipping of transmembrane domain.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack, NJ, Genomic Testing Cooperative, Irvine, CA, Irvine, CA, Hackensack University Medical Center,
Abstract
Distinguishing between cancer-related mutations and clonal hematopoiesis using cell-free RNA (cfRNA) expression levels in a machine learning model.Org: Genomic Testing Cooperative, Irvine, CA, Irvine, CA, Genomics Testing Cooperative, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack, NJ,
Abstract
EZH2/EZH1 inhibitor tulmimetostat (CPI-0209) in patients with advanced solid tumors or hematologic malignancies: Preliminary phase II results.Org: Swedish Cancer Institute, University of Leicester and Leicester University Hospitals, University Hospitals Of Leicester NHS Trust, Service d'hématologie clinique du CHU de Nantes, START Midwest, Grand Rapids, MI,
Abstract
Mortality rate and social disparity trends with tyrosine kinase inhibitory availability in chronic myelogenous leukemia: An analysis in the US from 1999 to 2020.Org: Hackensack University Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,
Abstract
A phase 1/2 study of the safety, tolerability, and preliminary efficacy of the anti-GITR monoclonal antibody, INCAGN01876, combined with immunotherapies (IO) in patients (Pts) with advanced cancers.Org: Hackensack University Medical Center, The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, Karmanos Cancer Institute, The Sarah Cannon Research Institute, Stephenson Cancer Center,
Abstract
Phase 3 TRIDENT study (EF-32): Tumor treating fields (TTFields; 200 kHz) concomitant with chemoradiation, and maintenance TTFields therapy/temozolomide in newly diagnosed glioblastoma.Org: Novocure Inc., Thomas Jefferson University, University of Montreal, Johns Hopkins University School of Medicine, Tufts Medical Center/Tufts University,
Abstract
Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack University Medical Center, Severance Hospital, Department of Neurosurgery and Neuro-Oncology, National Cancer Center Research Institute, Tokyo, Japan, National Cancer Center Research Institute,
Abstract
A phase II multi-cohort single-arm study of tiragolumab with atezolizumab plus bevacizumab in previously treated advanced non-squamous non–small-cell lung cancer.Org: Georgetown University Medical School, Patient Advocate, Johns Hopkins University School of Medicine, Hackensack University Medical Center,
Abstract
Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting.Org: University of California San Francisco, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Roswell Park Comprehensive Cancer Center, Hackensack University Medical Center, Portland VA Health Care System and OHSU Knight Cancer Institute,
Abstract
A phase I/II study of carfilzomib, iberdomide (CC-220), and dexamethasone (KID) in patients with newly diagnosed transplant-eligible multiple myeloma.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Center for Discovery and Innovation, Hackensack Meridian Health, Hackensack Meridian Health,
Abstract
A phase IIb study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Center for Discovery and Innovation, Hackensack Meridian Health, Hackensack Meridian Health,
Abstract
Hodgkin lymphoma mortality trends in age subgroups from 1999 to 2020 in the United States.Org: Hackensack University Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,
Abstract
Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment.Org: Vanderbilt University Medical Center, Hematology Department, Hospital Universitari i Politècnic La Fe, CHU Nantes-Department of Hepato-Gastroenterology, University of North Carolina School of Medicine, University of Wisconsin Health,